GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » Beneish M-Score

RemeGen Co (HKSE:09995) Beneish M-Score : -2.21 (As of Apr. 14, 2025)


View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.21 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for RemeGen Co's Beneish M-Score or its related term are showing as below:

HKSE:09995' s Beneish M-Score Range Over the Past 10 Years
Min: -2.21   Med: 31.38   Max: 72.78
Current: -2.21

During the past 7 years, the highest Beneish M-Score of RemeGen Co was 72.78. The lowest was -2.21. And the median was 31.38.


RemeGen Co Beneish M-Score Historical Data

The historical data trend for RemeGen Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Beneish M-Score Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beneish M-Score
Get a 7-Day Free Trial - - 31.38 -2.21 -

RemeGen Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.38 72.78 -2.21 - -

Competitive Comparison of RemeGen Co's Beneish M-Score

For the Biotechnology subindustry, RemeGen Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RemeGen Co's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where RemeGen Co's Beneish M-Score falls into.


;
;

RemeGen Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of RemeGen Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0725+0.528 * 0.8479+0.404 * 1.9703+0.892 * 1.3728+0.115 * 0.8923
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0892+4.679 * -0.0017-0.327 * 2.2422
=-2.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was HK$492 Mil.
Revenue was HK$1,177 Mil.
Gross Profit was HK$900 Mil.
Total Current Assets was HK$2,438 Mil.
Total Assets was HK$6,047 Mil.
Property, Plant and Equipment(Net PPE) was HK$3,328 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$263 Mil.
Selling, General, & Admin. Expense(SGA) was HK$1,191 Mil.
Total Current Liabilities was HK$1,244 Mil.
Long-Term Debt & Capital Lease Obligation was HK$1,001 Mil.
Net Income was HK$-1,653 Mil.
Gross Profit was HK$0 Mil.
Cash Flow from Operations was HK$-1,643 Mil.
Total Receivables was HK$334 Mil.
Revenue was HK$857 Mil.
Gross Profit was HK$556 Mil.
Total Current Assets was HK$3,587 Mil.
Total Assets was HK$6,724 Mil.
Property, Plant and Equipment(Net PPE) was HK$2,978 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$208 Mil.
Selling, General, & Admin. Expense(SGA) was HK$796 Mil.
Total Current Liabilities was HK$996 Mil.
Long-Term Debt & Capital Lease Obligation was HK$117 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(491.814 / 1177.048) / (334.041 / 857.386)
=0.417837 / 0.389604
=1.0725

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(555.941 / 857.386) / (900.173 / 1177.048)
=0.648414 / 0.764772
=0.8479

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2437.96 + 3327.806) / 6046.675) / (1 - (3587.042 + 2978.366) / 6723.953)
=0.046457 / 0.023579
=1.9703

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1177.048 / 857.386
=1.3728

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(208.123 / (208.123 + 2978.366)) / (262.812 / (262.812 + 3327.806))
=0.065314 / 0.073194
=0.8923

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1190.97 / 1177.048) / (796.483 / 857.386)
=1.011828 / 0.928967
=1.0892

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1001.095 + 1244.218) / 6046.675) / ((117.122 + 996.446) / 6723.953)
=0.37133 / 0.165612
=2.2422

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-1652.95 - 0 - -1642.669) / 6046.675
=-0.0017

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

RemeGen Co has a M-score of -2.21 suggests that the company is unlikely to be a manipulator.


RemeGen Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


RemeGen Co Business Description

Traded in Other Exchanges
Address
58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat major diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.
Executives
Fang Jianmin 2103 Interests held jointly with another person
Lin Jian 2103 Interests held jointly with another person
Wang Weidong 2201 Interest of corporation controlled by you
Wang Liqiang 2103 Interests held jointly with another person
Yi Fang Da Ji Jin Guan Li You Xian Gong Si 2102 Investment manager
Rongchang Holding Group Ltd. 2103 Interests held jointly with another person
Yantai Rongda Venture Capital Center (limited Partnership) 2103 Interests held jointly with another person
Yang Minhua 2103 Interests held jointly with another person
Xiong Xiaobin 2103 Interests held jointly with another person
Wen Qingkai 2103 Interests held jointly with another person
Wei Jianliang 2103 Interests held jointly with another person
Wang Xudong 2103 Interests held jointly with another person
I-nova Limited 2101 Beneficial owner
Deng Yong 2103 Interests held jointly with another person
Morgan Stanley 2201 Interest of corporation controlled by you

RemeGen Co Headlines

No Headlines